Mushroom extract tested to ease chemo side effects in ovarian cancer
NCT ID NCT05763199
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests whether a supplement called AHCC, made from cultured mushroom mycelia, can improve quality of life for ovarian cancer patients receiving standard chemotherapy. About 20 participants will take either AHCC or a placebo during their treatment. The main goal is to see if the study is feasible, not to prove effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells target a common ovarian cancer protein?
- Experimental pill takes on Hard-to-Treat ovarian cancer
- Radioactive antibody targets rare childhood cancer
- Radiation boost may Re-Sensitize ovarian cancer to PARP inhibitors
- Immunotherapy-Chemo combo before surgery shows promise for advanced ovarian cancer
- Exercise and diet counseling may help cancer patients finish chemo